Novel neutrophil autoantigens in systemic lupus erythematosus

Project: Research project

Description

DESCRIPTION (provided by applicant): Systemic lupus erythematosus (SLE) is an autoimmune disease affecting about 1.5 million Americans. At the devastating disease stage, abnormal immune response can target and destroy many vital organs. Neutrophils are at the frontier of innate immunity against infections. Neutrophil activation has also been linked to tissue injury in acute infections and autoimmune conditions. Using our collection of recombinant antibodies generated from single B cells of SLE patients, we found that a high frequency of SLE-derived recombinant antibodies bind to and activate neutrophils as examined by degranulation and oxidative burst. In particular, S4Ab2 antibody recognizes membrane bound protein disulfide isomerase (PDI) and also induces strong Ca++ influx and protein tyrosine phosphorylation in neutrophils;S4Ab4 antibody recognizes a novel pattern recognition receptor NLRC5/NOD27 and induces neutrophil extracellular trap (NET) formation. Furthermore, administration of S4Ab2 or S4Ab4 antibodies in NZB/W F1 mice induces kidney damage. Based on these results, we hypothesize that a subset of autoantibodies from SLE patients recognizes neutrophil antigens and activates neutrophils, which contributes to tissue damage in SLE. To test this hypothesis, (1) we will examine a large number of SLE-derived recombinant antibodies to identify autoantibodies that bind to and activate neutrophils. We will use these autoantibodies to identify their cognate antigens and determine if such autoantibodies can be used as biomarkers to predict tissue damage in SLE patients. (2) We will determine if SLE derived anti-neutrophil antibodies activate neutrophils through the classical Fc3 receptor pathway and further dissect their signaling pathways using different protein kinase inhibitors. We will also determine the specific signaling of S4Ab2 and S4Ab4 antibodies upon binding to their cognate antigens on neutrophils. (3) We will determine if SLE-derived anti-neutrophil autoantibodies induce tissue damage in murine lupus models. We will further test whether depletion of neutrophils or blocking of neutrophil activation can prevent the autoantibody-mediated tissue damage in murine models. Results from our studies will identify potential bio-markers for prediction of tissue damage in SLE and also help to develop novel preventive and therapeutic interventions for tissue damage in SLE patients. PUBLIC HEALTH RELEVANCE: Systemic lupus erythematosus (SLE) is an autoimmune disease affecting more than half a million Americans. At the devastating disease stage, abnormal immune response can target and destroy many vital organs. Although neutrophils are the frontiers of innate immunity against infections, excessive neutrophil activation has been linked to tissue injury in acute infections and autoimmune conditions. Our current studies showed that SLE-derived autoantibodies directly react with neutrophil antigens and activate neutrophils and thus, contribute to tissue damage. Results from our proposed studies will shed new lights on understanding the mechanism of autoantibody-mediated tissue damage and will allow us to design specific treatments to prevent tissue damage in SLE patients.
StatusFinished
Effective start/end date9/12/118/31/16

Funding

  • National Institutes of Health: $285,677.00
  • National Institutes of Health: $300,713.00
  • National Institutes of Health: $300,713.00
  • National Institutes of Health: $300,713.00
  • National Institutes of Health: $294,698.00

Fingerprint

Autoantigens
Systemic Lupus Erythematosus
Neutrophils
Autoantibodies
Antibodies
Neutrophil Activation
Antigens
Protein Disulfide-Isomerases
Pattern Recognition Receptors
Infection
Respiratory Burst
Innate Immunity
Autoimmune Diseases
Protein Kinase Inhibitors
Tyrosine
Anti-Idiotypic Antibodies
Membrane Proteins
B-Lymphocytes
Biomarkers
Phosphorylation

ASJC

  • Medicine(all)